178 related articles for article (PubMed ID: 15715472)
41. [Effects of curcumin on the acetylation of histone H3, P53 and the proliferation of NB4 cells].
Li XG; Chen Y; Wu Q; Liu HL
Zhonghua Xue Ye Xue Za Zhi; 2005 Sep; 26(9):551-3. PubMed ID: 16468334
[TBL] [Abstract][Full Text] [Related]
42. Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors.
Lu Q; Yang YT; Chen CS; Davis M; Byrd JC; Etherton MR; Umar A; Chen CS
J Med Chem; 2004 Jan; 47(2):467-74. PubMed ID: 14711316
[TBL] [Abstract][Full Text] [Related]
43. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
[TBL] [Abstract][Full Text] [Related]
44. Novel multifunctional acyloxyalkyl ester prodrugs of 5-aminolevulinic acid display improved anticancer activity independent and dependent on photoactivation.
Berkovitch G; Doron D; Nudelman A; Malik Z; Rephaeli A
J Med Chem; 2008 Dec; 51(23):7356-69. PubMed ID: 19007111
[TBL] [Abstract][Full Text] [Related]
45. The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs.
Rephaeli A; Entin-Meer M; Angel D; Tarasenko N; Gruss-Fischer T; Bruachman I; Phillips DR; Cutts SM; Haas-Kogan D; Nudelman A
Invest New Drugs; 2006 Sep; 24(5):383-92. PubMed ID: 16502348
[TBL] [Abstract][Full Text] [Related]
46. The chemopreventive activity of the butyric acid prodrug tributyrin in experimental rat hepatocarcinogenesis is associated with p53 acetylation and activation of the p53 apoptotic signaling pathway.
de Conti A; Tryndyak V; Koturbash I; Heidor R; Kuroiwa-Trzmielina J; Ong TP; Beland FA; Moreno FS; Pogribny IP
Carcinogenesis; 2013 Aug; 34(8):1900-6. PubMed ID: 23568954
[TBL] [Abstract][Full Text] [Related]
47. Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity.
Rephaeli A; Waks-Yona S; Nudelman A; Tarasenko I; Tarasenko N; Phillips DR; Cutts SM; Kessler-Icekson G
Br J Cancer; 2007 Jun; 96(11):1667-74. PubMed ID: 17473824
[TBL] [Abstract][Full Text] [Related]
48. Doxorubicin-formaldehyde conjugate, doxoform: induction of apoptosis relative to doxorubicin.
Burke PJ; Koch TH
Anticancer Res; 2001; 21(4A):2753-60. PubMed ID: 11724351
[TBL] [Abstract][Full Text] [Related]
49. Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9).
Cutts SM; Rephaeli A; Nudelman A; Hmelnitsky I; Phillips DR
Cancer Res; 2001 Nov; 61(22):8194-202. PubMed ID: 11719450
[TBL] [Abstract][Full Text] [Related]
50. Esterase inhibitors diminish the modulation of gene expression by butyric acid derivative, pivaloyloxymethyl butyrate (AN-9).
Rabizadeh E; Shaklai M; Eisenbach L; Nudelman A; Rephaeli A
Isr J Med Sci; 1996 Dec; 32(12):1186-91. PubMed ID: 9007151
[TBL] [Abstract][Full Text] [Related]
51. Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: efficacy of tributyrin, a butyric acid prodrug.
Kuroiwa-Trzmielina J; de Conti A; Scolastici C; Pereira D; Horst MA; Purgatto E; Ong TP; Moreno FS
Int J Cancer; 2009 Jun; 124(11):2520-7. PubMed ID: 19195022
[TBL] [Abstract][Full Text] [Related]
52. Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft.
Tarasenko N; Nudelman A; Rozic G; Cutts SM; Rephaeli A
Invest New Drugs; 2017 Aug; 35(4):412-426. PubMed ID: 28315153
[TBL] [Abstract][Full Text] [Related]
53. 1,4-Bis(1-naphthyl)-2,3-dinitro-1,3-butadiene a novel anticancer compound effective against tumor cell lines characterized by different mechanisms of resistance.
Novi M; Ottone M; Dell'Erba C; Barbieri F; Chiavarina B; Maccagno M; Viale M
Oncol Rep; 2004 Jul; 12(1):91-6. PubMed ID: 15201965
[TBL] [Abstract][Full Text] [Related]
54. Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases.
Nudelman A; Gnizi E; Katz Y; Azulai R; Cohen-Ohana M; Zhuk R; Sampson SR; Langzam L; Fibach E; Prus E; Pugach V; Rephaeli A
Eur J Med Chem; 2001 Jan; 36(1):63-74. PubMed ID: 11231050
[TBL] [Abstract][Full Text] [Related]
55. Antiproliferative and phenotype-transforming antitumor agents derived from cysteine.
Glenn MP; Kahnberg P; Boyle GM; Hansford KA; Hans D; Martyn AC; Parsons PG; Fairlie DP
J Med Chem; 2004 Jun; 47(12):2984-94. PubMed ID: 15163181
[TBL] [Abstract][Full Text] [Related]
56. Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas.
Entin-Meer M; Rephaeli A; Yang X; Nudelman A; VandenBerg SR; Haas-Kogan DA
Mol Cancer Ther; 2005 Dec; 4(12):1952-61. PubMed ID: 16373710
[TBL] [Abstract][Full Text] [Related]
57. Stereoselective hydrolysis of xenobiotic esters by different cell lines from rat liver and hepatoma and its application to chiral prodrugs for designated growth suppression of cancer cells.
Kageyama Y; Yamazaki Y; Afify AS; Ogawa Y; Okada T; Okuno H
Chirality; 1995; 7(4):297-304. PubMed ID: 7640174
[TBL] [Abstract][Full Text] [Related]
58. Butyric acid and its monosaccharide ester induce apoptosis in the HL-60 cell line.
Calabresse C; Venturini L; Ronco G; Villa P; Chomienne C; Belpomme D
Biochem Biophys Res Commun; 1993 Aug; 195(1):31-8. PubMed ID: 8363611
[TBL] [Abstract][Full Text] [Related]
59. Histone deacetylase inhibitor prodrugs in nanoparticle vector enhanced gene expression in human cancer cells.
Ishii Y; Hattori Y; Yamada T; Uesato S; Maitani Y; Nagaoka Y
Eur J Med Chem; 2009 Nov; 44(11):4603-10. PubMed ID: 19632009
[TBL] [Abstract][Full Text] [Related]
60. New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation.
Mansour OC; Evison BJ; Sleebs BE; Watson KG; Nudelman A; Rephaeli A; Buck DP; Collins JG; Bilardi RA; Phillips DR; Cutts SM
J Med Chem; 2010 Oct; 53(19):6851-66. PubMed ID: 20860366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
